Cabaletta Bio Announces 2026 Strategic Priorities Registrational myositis trial actively enrolling with planned 17-patient cohort and 2027 rese-cel BLA submission – including an outpatient dosing option using a single weight-based dose IND amendment cleared to manufacture rese-cel with the automated, scalable Cellares platform based on multiple successful engineering runs; clinical manufacturing data expected in 1H26 to confirm GMP readiness, including supply chain logistics New durability data without preconditioning and higher dose initial clinical data from RESET-PV™ expected in 1H26...
Moody's Ratings (Moody's) has completed a periodic review of the ratings of Clear Channel Outdoor Holdings, Inc. and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 17 December 2025 in which we reassessed the appropriateness of the rat...
Dave & Buster’s Reports Third Quarter 2025 Financial Results DALLAS, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Dave & Buster's Entertainment, Inc. (NASDAQ: PLAY) (“Dave & Buster's” or “the Company”), an owner, operator, and franchisor of entertainment and dining venues, today announced financial results for its third quarter of fiscal 2025 ended November 4, 2025. Third Quarter 2025 Financial Summary Third quarter revenue was $448.2 million, a 1.1% decrease compared to the third quarter of fiscal 2024.Third quarter comparable store sales decreased 4.0% compared to the same calendar period in fis...
Dave & Buster’s Entertainment, Inc. to Report Third Quarter 2025 Financial Results on December 9, 2025 DALLAS, Nov. 28, 2025 (GLOBE NEWSWIRE) -- Dave & Buster's Entertainment, Inc., (NASDAQ:PLAY), ("Dave & Buster's" or "the Company"), an owner, operator, and franchisor of entertainment and dining venues, today announced that it will report financial results for its third quarter ended November 4, 2025 after the market closes on Tuesday, December 9, 2025. Management will host a conference call to discuss these results on Tuesday, December 9, 2025, at 4:00 p.m. Central Time (5:00 p.m. East...
Cabaletta Bio Reports Third Quarter 2025 Financial Results and Provides Business Update Rese-cel data presented at multiple medical meetings demonstrated potentially transformative, drug-free clinical responses with a favorable safety profile for autoimmune patients supporting outpatient use All myositis patients in the Phase 1/2 DM/ASyS cohort with sufficient follow-up who would have met key criteria for the registrational cohort met the registrational, 16-week primary endpoint Planned BLA submission for rese-cel in 2027 based on 14-patient, single-arm DM/ASyS registrational cohort initi...
Cabaletta Bio to Participate in Upcoming Investor Conferences in November and December PHILADELPHIA, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced that the Company will participate in the following upcoming investor conferences in November and December: Guggenheim’s 2nd Annual Healthcare Innovation Conference: Webcasted fireside chat at 10:30 a.m. ET on Tuesday, November 1...
Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.
Cabaletta Bio Presents Positive Clinical Data and Development Updates for Rese-cel at ACR Convergence 2025 – All myositis patients in the Phase 1/2 DM/ASyS cohort with sufficient follow-up who met key registrational inclusion criteria exceeded the registrational primary endpoint, demonstrating major TIS responses with no immunomodulators – – Myositis registrational trial being initiated this quarter with a planned cohort of 14 DM/ASyS patients and a 16-week primary endpoint – moderate or major TIS while off immunomodulators and on no or low-dose steroids – consistent with FDA alignment on ...
Cabaletta Bio Announces Appointment of Steve Gavel as Chief Commercial Officer and Award of Inducement Grant – Gavel brings highly relevant CAR T experience from Legend Biotech where he led the launch and commercialization of CARVYKTI® from 2018 until 2025 – PHILADELPHIA, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced the appointment of Steve Gavel as Chief Commercial Offic...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.